Rayos sunshine for Horizon: US FDA grants OK for RA drug
This article was originally published in Scrip
Executive Summary
Horizon Pharma gained the blessing from the US FDA to market the company's delayed-release low-dose prednisone tablet Rayos (prednisone) not only for rheumatoid arthritis (RA), but also for a broad range of other diseases – polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease (COPD).